Bifogade filer
Kurs
-1,82%
Likviditet
0,14 MSEK
Kalender
Tid* | ||
2025-05-16 | N/A | Årsstämma |
2025-02-28 | 08:00 | Bokslutskommuniké 2024 |
2024-11-20 | - | Kvartalsrapport 2024-Q3 |
2024-09-04 | - | Extra Bolagsstämma 2024 |
2024-08-28 | - | Kvartalsrapport 2024-Q2 |
2024-05-28 | - | Kvartalsrapport 2024-Q1 |
2024-05-15 | - | X-dag ordinarie utdelning ISAB 0.00 SEK |
2024-05-14 | - | Årsstämma |
2024-02-28 | - | Bokslutskommuniké 2023 |
2023-11-22 | - | Kvartalsrapport 2023-Q3 |
2023-08-29 | - | Kvartalsrapport 2023-Q2 |
2023-05-31 | - | Kvartalsrapport 2023-Q1 |
2023-05-15 | - | X-dag ordinarie utdelning ISAB 0.00 SEK |
2023-05-12 | - | Årsstämma |
2023-02-28 | - | Bokslutskommuniké 2022 |
2022-11-22 | - | Kvartalsrapport 2022-Q3 |
2022-08-29 | - | Kvartalsrapport 2022-Q2 |
2022-06-08 | - | X-dag ordinarie utdelning ISAB 0.00 SEK |
2022-05-23 | - | Kvartalsrapport 2022-Q1 |
2022-05-06 | - | Årsstämma |
2022-02-28 | - | Bokslutskommuniké 2021 |
2021-11-24 | - | Kvartalsrapport 2021-Q3 |
2021-08-26 | - | Kvartalsrapport 2021-Q2 |
2021-06-22 | - | Extra Bolagsstämma 2021 |
2021-06-09 | - | X-dag ordinarie utdelning ISAB 0.00 SEK |
2021-06-08 | - | Årsstämma |
2021-05-19 | - | Kvartalsrapport 2021-Q1 |
2021-02-25 | - | Bokslutskommuniké 2020 |
2020-11-26 | - | Kvartalsrapport 2020-Q3 |
2020-08-26 | - | Kvartalsrapport 2020-Q2 |
2020-06-12 | - | Extra Bolagsstämma 2020 |
2020-05-13 | - | X-dag ordinarie utdelning ISAB 0.00 SEK |
2020-05-12 | - | Årsstämma |
2020-05-07 | - | Kvartalsrapport 2020-Q1 |
2020-02-20 | - | Bokslutskommuniké 2019 |
2019-11-14 | - | Kvartalsrapport 2019-Q3 |
2019-08-22 | - | Kvartalsrapport 2019-Q2 |
2019-05-22 | - | Årsstämma |
2019-05-16 | - | Kvartalsrapport 2019-Q1 |
2019-05-10 | - | X-dag ordinarie utdelning ISAB 0.00 SEK |
2019-02-21 | - | Bokslutskommuniké 2018 |
2018-12-13 | - | Extra Bolagsstämma 2018 |
2018-11-15 | - | Kvartalsrapport 2018-Q3 |
2018-08-22 | - | Kvartalsrapport 2018-Q2 |
2018-05-24 | - | X-dag ordinarie utdelning ISAB 0.00 SEK |
2018-05-23 | - | Årsstämma |
2018-05-16 | - | Kvartalsrapport 2018-Q1 |
2018-02-22 | - | Bokslutskommuniké 2017 |
2017-11-17 | - | Kvartalsrapport 2017-Q3 |
2017-08-28 | - | Kvartalsrapport 2017-Q2 |
Beskrivning
Land | Sverige |
---|---|
Lista | Spotlight |
Sektor | Hälsovård |
Industri | Medicinteknik |
(Stockholm 18 October 2022) Inhalation Research Services (IRS) has received a revised order increasing the amount that it will be paid by a US pharma company. The original order, communicated on 18 July 2022, was for 136,000 Euro. This has now been raised to 151,000 Euro as additional steps within the research project have been contracted out to IRS by the client.
ISAB's world-class expertise in inhalation, and its high-precision IPL (Isolated Perfused Lung) ex vivo method, were decisive in the client's choice of IRS for research into a new repurposed drug being reformulated for administration via the lungs.
ISAB CEO Manoush Masarrat: "We are pleased with the confidence our client has shown in Inhalation Research Services and our technology."
Manoush Masarrat, CEO
E-mail: Manoush.masarrat@inhalation.se
Mobile: +46 (0)73 628 9153